Navigation Links
Roche Exercises its Option to Further Develop and Commercialize Memory Pharmaceuticals' Nicotinic Alpha-7 Agonist, MEM 3454
Date:5/2/2008

d is currently being evaluated in a Phase 2a trial in CIAS, with top-line results expected in the fourth quarter of 2008. The trial is expected to enroll approximately 160 patients and is designed to assess the safety, tolerability and cognitive effects of three doses of MEM 3454 in patients with CIAS. In addition, Memory Pharmaceuticals and Roche recently expanded their schizophrenia development program for MEM 3454 to include a biomarker study, which will be funded by Roche. Memory Pharmaceuticals expects to initiate the biomarker trial this summer, with results expected by early 2009.

MEM 3454 is a partial agonist of the nicotinic alpha-7 receptor, a highly specialized receptor found in the central nervous system. Compounds acting on this receptor could be beneficial in the treatment of Alzheimer's disease and schizophrenia, as well as other psychiatric and neurological disorders.

Conference Call Information

Memory Pharmaceuticals will hold a conference call today, May 2, 2008 at 9:00 a.m. EDT to discuss this announcement. The conference call will also be broadcast live from the "Investors" section of the Company's website. Memory Pharmaceuticals' senior management will host the conference call. Investors and other interested parties may access the call as follows:

Date: Friday, May 2, 2008

Time: 9:00 a.m. EDT

Telephone (U.S.): 866.314.4483

Telephone (international): 617.213.8049

Participant Passcode: 38691567

Webcast: http://www.memorypharma.com under the

"Investors" section

An audio replay of the conference call will be available from 11:00 a.m. EDT on Friday, May 2, 2008, until Friday, May 9, 2008. To access the replay, please dial 888.286.8010 (U.S.) or 617.801.6888 (international) and enter passcode number 95627100. An au
'/>"/>

SOURCE Memory Pharmaceuticals Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Roche Gains Access to Important Oncology Target With Potential for Treating Major Cancers Such as Breast and Lung; First Drug Candidate in Phase I Clinical Testing
2. MacroChem Announces Presentation of Pexiganan Phase 3 Study Results for Topical Treatment of Diabetic Foot Infection
3. Memory Pharmaceuticals & Roche Expand Development Program for MEM 3454 in Schizophrenia
4. Roche and Pharmasset To Present the R7128 Monotherapy Resistance Profile
5. Roche responds to announcement of IDEAL hepatitis C trial results
6. Roche Submits Application for FDA Approval of ACTEMRA(R) for the Treatment of Rheumatoid Arthritis
7. Two Pivotal Phase III Studies for Roches ACTEMRA(TM) (tocilizumab) Demonstrate Significant Improvement in Rheumatoid Arthritis Symptoms
8. Roches Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks
9. Roche Diagnostics HIV Viral Load Test Used in Clinical Trials for Isentress, a New Class of HIV Drug
10. Roche Announces Positive Results in Solid Tumors Using Human Monoclonal Antibody Against IGF-1R (R1507)
11. MacroChem Acquires Rights to Pexiganan, a Novel Topical Anti-Infective for Treatment of Diabetic Foot Infections, From Genaera
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)...   Assurex Health, a personalized medicine company ... for behavioral health and chronic pain conditions, today ... equity financing from new and existing investors, according ... Chief Executive Officer. The financing will ... Health,s GeneSight ®  products.  GeneSight,s patented ...
(Date:12/24/2014)... Dec. 23, 2014 Tianyin Pharmaceutical Co., ... specializes in patented biopharmaceutical, modernized traditional Chinese medicine ... today announced that the Company achieved the Public ... Practice (GMP) certificate of TPI,s Qionglai Facility (QLF) ... The public notice period is a significant procedure ...
(Date:12/24/2014)... CHAPEL HILL, N.C. , Dec. 23, 2014 /PRNewswire/ ... marketplace success. As the key link between the medical ... will grow even more in the coming years as ... relationships. According to research by benchmarking ... and MSLs can gain an important edge is by ...
Breaking Medicine Technology:Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 2Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 3Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 4TPI QLF Achieved Public Notice Status of GMP Certification 2TPI QLF Achieved Public Notice Status of GMP Certification 3Role of Medical Science Liaisons Evolving in Medical Device Sector 2
(Date:12/24/2014)... Dr. Vu Ho, a Dallas based ... practice and med-spa with the addition of new Silk ... cosmetic treatments and services. , “Silk Peel is a ... Dr. Ho. “As a result it can address issues ... spots, discolorations or blemishes.” , Similar to microdermabrasion, ...
(Date:12/24/2014)... Wilsonville, Oregon (PRWEB) December 24, 2014 ... Infinity Rehab sat down with Derek Fenwick, PT, ... legislative changes that will stem from the passing of ... 2014 (IMPACT Act). In this taping of the ... amends title XVIII of the Social Security Act to ...
(Date:12/24/2014)... 24, 2014 (HealthDay News) -- A new, injectable weight-loss ... Drug Administration. The agency on Tuesday approved Saxenda ... who are overweight and have at least one weight-related ... diabetes or high cholesterol. Patients taking the drug, ... diet and exercise regularly, the FDA noted. "Obesity ...
(Date:12/24/2014)... Steven Reinberg HealthDay Reporter ... guidelines from the American Diabetes Association (ADA) call for giving ... diabetes to help prevent heart disease. These new standards ... Cardiology and American Heart Association, which also recommend giving low- ... disease, including people with diabetes. "We agree that the ...
(Date:12/24/2014)... 2014 The 2014 Market Research ... and in-depth research report on COC industry. For ... information, including its definition, classification, application, industry chain ... This report also presents product specification, manufacturing process, ... by regions, technology and applications. Analysis also covers ...
Breaking Medicine News(10 mins):Health News:Dr. Vu Ho Expands Facial Plastic Surgery Practice to Include New Skin Care Treatment 2Health News:Latest Episode of Infinicast Features Infinity Rehab President Discussing IMPACT Act of 2014 and Changes for Post-Acute Therapy Providers in 2015 2Health News:FDA Approves New Weight-Loss Drug 2Health News:FDA Approves New Weight-Loss Drug 3Health News:Nearly All Diabetics Should Be on Cholesterol-Lowering Drugs: Experts 2Health News:Nearly All Diabetics Should Be on Cholesterol-Lowering Drugs: Experts 3Health News:COC/ Cyclic Olefin Copolymer Market: Global 2015-2020 Forecasts & Research Report Now at DeepResearchReports.com 2Health News:COC/ Cyclic Olefin Copolymer Market: Global 2015-2020 Forecasts & Research Report Now at DeepResearchReports.com 3
... Using a novel imaging technique to study autistic children, ... areas that govern social processing and learning by observation. ... Lindner Center for Autism, North Shore-Long Island Jewish Health ... annual meeting of the Radiological Society of North America ...
... Advanced Laparoscopic Procedures through the Belly Button: Scar-Free ... ... CLEVELAND, Nov. 28 Cleveland Clinic urologists recently,performed a ... pyeloplasty (uretero-pelvic,junction repair), ileal ureter replacement, and psoas hitch uretero-,neocystostomy ...
... Inc., a leading,provider of medical image review services ... million Series B financing led by Siemens Venture,Capital ... Tang Capital Management participated in the financing., ... imaging and clinical,research, and we are delighted to ...
... of Transplantation Winter Symposium Kicks Off March ... ... Organ transplantation is,increasingly being offered to patients with multiple co-morbidities and ... has prompted the increasing use of donors with characteristics,that increase the risk ...
... first comprehensive review of evidence on pneumococcal conjugate vaccination ... the on-line edition of the journal Lancet Infectious Diseases, ... pneumococcal infection by up to 40 fold, that the ... and that the vaccine can protect HIV-infected infants. ...
... in Energy-based Surgical Systems Uses Intelligent Device Management,to ... Technologies, BOULDER, Colo. and REDWOOD CITY, Calif., ... ; BSX: COV), a world leader in advanced,energy-based ... Device Management (IDM), today announced the global launch ...
Cached Medicine News:Health News:Novel imaging technique shows gray matter increase in brains of autistic children 2Health News:World Firsts by Cleveland Clinic Urologists 2Health News:RadPharm Announces $10 million Series B Financing, led by Siemens Venture Capital 2Health News:RadPharm Announces $10 million Series B Financing, led by Siemens Venture Capital 3Health News:AST 'Emergence to Convergence' Highlights the Latest High-Risk Organ Donor and Recipient Issues 2Health News:Pneumococcal conjugate vaccines can improve the lives of HIV-infected children 2Health News:Covidien Launches First-In-Class, Questra-Based Valleylab(TM) Exchange Software Update System 2Health News:Covidien Launches First-In-Class, Questra-Based Valleylab(TM) Exchange Software Update System 3
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: